The company said that the drugs removed from the formulary have alternatives that cost less, including generics, and some of those removed were nonpreferred drugs with lower degrees of utilization, according to the WSJ, adding that the removals are considered voluntary, but clients using the PBM's services risk getting a smaller share of rebates if they don't follow the policy.